Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 15/20 | 0.81 |
| ▸ | MMP1 | P03956 | 14/20 | 0.81 |
| ▸ | MMP9 | P14780 | 14/20 | 0.81 |
| ▸ | MMP13 | P45452 | 14/20 | 0.81 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.81 |
| ▸ | MMP2 | P08253 | 1/20 | 0.81 |
| ▸ | MMP3 | P08254 | 1/20 | 0.81 |
| ▸ | MMP7 | P09237 | 1/20 | 0.81 |
| ▸ | MMP8 | P22894 | 1/20 | 0.81 |
| ▸ | MMP14 | P50281 | 1/20 | 0.81 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7409543 | 0.89 | ADAM17 (1.00) | ADAM17MMP1MMP9MMP13ADAMTS4 | |
| SCHEMBL7366311 | 0.89 | ADAM17 (0.78) | ADAM17MMP1MMP9MMP13ADAMTS4 | |
| SCHEMBL7410572 | 0.88 | ALDH1A1 (0.90) | ADAM17MMP1MMP9MMP13ADAMTS4 | |
| SCHEMBL7623960 | 0.87 | ADAM17 (0.76) | ADAM17MMP1MMP9MMP13ADAMTS4 | |
| SCHEMBL6567121 | 0.86 | MMP1 (0.80) | ADAM17MMP1MMP9MMP13ADAMTS4 | |
| SCHEMBL7405390 | 0.86 | MMP13 (0.78) | ADAM17MMP1MMP9MMP13ADAMTS4 | |
| SCHEMBL7412158 | 0.85 | MMP13 (0.80) | ADAM17MMP1MMP9MMP13ADAMTS4 | |
| SCHEMBL7403023 | 0.83 | MMP9 (0.80) | ADAM17MMP1MMP9MMP13ADAMTS4 | |
| SCHEMBL6565390 | 0.83 | MMP9 (0.81) | ADAM17MMP1MMP9MMP13ALDH1A1 | |
| SCHEMBL7406917 | 0.82 | MMP13 (0.77) | ADAM17MMP1MMP9MMP13ADAMTS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0517852-B1 | TRI- AND TETRA-SUBSTITUTED GUANIDINES AND THEIR USE AS EXCITATORY AMINO ACID ANTAGONISTS | OREGON STATE (US) | 2002-07-10 | — | — | EP | claimed |
| US-20020188120-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl, or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | AMERICAN CYANAMID COMPANY (US) | 2002-12-12 | — | — | US | disclosed |
| EP-1252143-A1 | METHOD FOR PREPARING ALPHA-SULFONYL HYDROXAMIC ACID DERIVATIVES | American Cyanamid Company (US) | 2002-10-30 | — | — | EP | disclosed |
| WO-2002083112-A2 | METHOD FOR THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE | WYETH HOLDINGS CORPORATION (US) | 2002-10-24 | — | — | WO | disclosed |
| US-6462073-B2 | METALLOPROTEASE INHIBITORS | AMERICAN HOME PRODUCTS CORPORATION | 2002-10-08 | — | — | US | disclosed |
| US-6441023-B1 | FOR THERAPY OF ARTHRITIS, TUMOR METASTASIS, TISSUE ULCERATION, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, DIABETES (INSULIN RESISTANCE) AND HIV INFECTION | AMERICAN HOME PRODUCTS CORPORATION | 2002-08-27 | — | — | US | disclosed |
| US-20020099035-A1 | Method for preparing alpha-sulfonyl hydroxamic acid derivatives | WYETH HOLDINGS CORPORATION | 2002-07-25 | — | — | US | disclosed |
| US-20020032186-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | AMERICAN CYANAMID COMPANY (US) | 2002-03-14 | — | — | US | disclosed |
| US-20020006922-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | AMERICAN CYANAMID COMPANY (US) | 2002-01-17 | — | — | US | disclosed |
| US-6331563-B1 | LOW MOLECULAR WEIGHT, NON-PEPTIDE INHIBITORS OF MATRIX METALLOPROTEINASES AND TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME; TREATING ARTHRITIS, TUMOR METASTASIS, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, INSULIN RESISTANCE | WYETH HOLDINGS CORPORATION | 2001-12-18 | — | — | US | disclosed |
| US-6288086-B1 | COMPOUNDS SUCH AS 1-METHYL-4-(4-BUTOXY-BENZENESULFONYL) -PIPERIDINE-4-CARBOXYLIC ACID HYDROXYAMIDE USED TO TREAT ARTHRITIS, TUMOR METASTASIS, TISSUE ULCERATION, ABNORMAL WOUND HEALING, ETC.; LOW MOLECULAR WEIGHT AND NON-PEPTIDAL | AMERICAN CYANAMID COMPANY | 2001-09-11 | — | — | US | disclosed |
| WO-2001055112-A1 | METHOD FOR PREPARING ALPHA-SULFONYL HYDROXAMIC ACID DERIVATIVES | AMERICAN CYANAMID COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
| US-6197791-B1 | ANTIARTHRITIC AGENTS; WOUND HEALING AGENTS; ANTITUMOR AGENTS | AMERICAN CYANAMID COMPANY | 2001-03-06 | — | — | US | disclosed |
| EP-1054858-A1 | N-HYDROXY-2-(ALKYL, ARYL, OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED-ALKYL, ARYL OR HETEROARYLAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS | American Cyanamid Company (US) | 2000-11-29 | — | — | EP | disclosed |
| WO-1999042436-A1 | N-HYDROXY-2-(ALKYL, ARYL, OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED-ALKYL, ARYL OR HETEROARYLAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1999-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032186-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | MMP12, ADAM33, MMP2 | ADAM17 5/4885MMP1 4/4885MMP9 13/4885 |
| US-20020188120-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl, or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | MMP12, ADAM33, MMP2 | ADAM17 6/4885MMP1 8/4885MMP9 16/4885 |
| US-20020099035-A1 | Method for preparing alpha-sulfonyl hydroxamic acid derivatives | MMP25, ADAMTS5, MMP9 | ADAM17 4/4885MMP1 14/4885MMP9 3/4885 |
| US-20020006922-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | MMP12, ADAM33, MMP2 | ADAM17 5/4885MMP1 7/4885MMP9 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.